Halozyme Therapeutics Stock Math Operators Price Series Summation
| HALO Stock | USD 67.81 -0.33 -0.48% |
| Symbols |
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Halozyme Therapeutics Price Series Summation is a cross summation of Halozyme Therapeutics price series and its benchmark/peer.
Halozyme Therapeutics Technical Analysis Modules
Most technical analysis of Halozyme Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Halozyme from various momentum indicators to cycle indicators. When you analyze Halozyme charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California. Halozyme Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 145 people. This overview emphasizes how Halozyme Therapeutics compares to peers on valuation quality and operating consistency. Current metrics include P/E of 60.08, P/B of 162.88, profit margin of 22.69%. Halozyme Therapeutics has market cap of 8.04 B, P/E of 60.08, ROE of 1.54%.
Methodology
Unless otherwise specified, financial data for Halozyme Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Halozyme (USA Stocks:HALO) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Halozyme Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR. Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Halozyme Therapeutics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Become your own money manager
Tracking Halozyme Therapeutics inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Did you try this?
Run Options Analysis Now
Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios |
| All Next | Launch Module |
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Macroaxis Index Invested few shares | |
 | Investor Favorites Invested over 60 shares | |
 | Advertising Invested few shares | |
 | Driverless Cars Invested over 200 shares | |
 | Hedge Favorites Invested over 20 shares | |
 | Corona Opportunity Invested few shares | |
 | Warren Buffett Holdings Invested over 20 shares | |
 | Power Assets Invested over 200 shares | |
 | Momentum Invested few shares |
More Resources for Halozyme Stock Analysis
A comprehensive view of Halozyme Therapeutics starts with financial statements and ratio context. Key ratios help frame profitability, efficiency, and growth context for Halozyme Therapeutics Stock. Key reports that frame Halozyme Therapeutics Stock are listed below:Halozyme Therapeutics has market cap of 8.04 B, P/E of 60.08, operating margin of 56.31%. Review Risk vs Return Analysis for broader portfolio context. This reflects a position in Halozyme Therapeutics in the portfolio view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. Our How to Invest in Halozyme Therapeutics guide provides practical guidance on trading Halozyme Stock.Analysis related to Halozyme Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Halozyme Therapeutics market price can diverge from book value, the accounting figure shown on Halozyme balance sheet. Halozyme Therapeutics' market capitalization is 8.04 B. With a P/B ratio of 162.88, the market values Halozyme Therapeutics well above its book equity. Enterprise value stands at 9.95 B. Intrinsic value is an analytical estimate of Halozyme Therapeutics' underlying worth that can differ from price and book value. Valuation methods help interpret those gaps.
It is useful to distinguish Halozyme Therapeutics' value from its trading price, which are computed with different methods. For Halozyme Therapeutics, key inputs include a P/E ratio of 60.08, a P/B ratio of 162.88, a profit margin of 22.69%, ROE of 1.54%. By contrast, market price reflects the level where buyers and sellers transact.